Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2014. Refer to TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | imatinib (Glivec®) | ||
| Formulation | 100 mg and 400 mg film-coated tablet | ||
| Reference number | 1653 | ||
| Indication | Adjuvant treatment, for up to 36 months, of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1653 | ||
| NMG meeting date | 14/05/2014 | ||
| AWMSG meeting date | 11/06/2014 | ||
| Ratification by Welsh Government | 24/07/2014 | ||
| Date of issue | 25/07/2014 | ||
| Date of last review | 08/05/2017 | ||
| NICE guidance | TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
||